Ripretinib | B3106

Ripretinib is an inhibitor of receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA). In vitro kinase inhibition studies show that ripretinib inhibits wild-type KIT and PDGFRA with IC₅₀ values of 3 and 3.6 nM. It is approved for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with 3 kinase inhibitors.

Ripretinib is an inhibitor of receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA). In vitro kinase inhibition studies show that ripretinib inhibits wild-type KIT and PDGFRA with IC₅₀ values of 3 and 3.6 nM. It is approved for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with 3 kinase inhibitors.

B3106 | Ripretinib DataSheet

Alternate Name/Synonyms: N-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3- yl]-2-fluorophenyl}-N'-phenylurea; DCC-2618; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea

Appearance: White to off-white powder

Formulation:

CAS Number: 1442472-39-0

Structure Available?: TRUE

Peptide sequence:

Salt Form: FALSE

Molecular Formula: C₂₄H₂₁BrFN₅O₂

Molecular Weight: 510.4

Cell-Permeable?: True

Purity: ≥ 98%

Solubilities:

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An inhibitor of receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA)

MDL Number: MFCD31657437

PubChem CID: 71584930

SMILES: CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC

InChi: InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

InChi Key: CEFJVGZHQAGLHS-UHFFFAOYSA-N